ViGeneron Rebrands as VeonGen, Earns FDA RPDD for Gene TherapyJun 16, 2025VeonGen Therapeutics has officially announced its rebranding from ViGeneron, marking a strategic transformation into a clinical-stage genetic medicine company dedicated to developing innovative gene therapies for diseases with high unmet medical needs.
Nicox Partners with Kowa for U.S. and Global Commercialization of NCX 470Jul 18, 2025Nicox S.A. has entered into a significant licensing agreement with Kowa Company, Ltd., granting Kowa the exclusive rights to develop and commercialize NCX 470 in the United States and all other unlicensed territories worldwide.
FDA Accepts Aldeyra’s Resubmitted NDA for Reproxalap in Dry Eye DiseaseJul 18, 2025The U.S. Food and Drug Administration (FDA) has accepted for review Aldeyra Therapeutics’ resubmitted New Drug Application (NDA) for reproxalap, an investigational therapy intended to treat the signs and symptoms of dry eye disease (DED).
Relative Peripheral Refraction Found to Predict Myopia Progression in ChildrenJul 04, 2025New research published online in the American Journal of Ophthalmology has shown that vertical and horizontal relative peripheral refraction (RPR) are associated with faster axial length progression and an increased risk of developing myopia in children.
2024 Recap: Top 8 FDA Approvals in Ophthalmology Dec 16, 2024The year 2024 has been a pivotal one for ophthalmology, with several novel FDA approvals introducing innovative treatments and technologies to the field